Since our June 2 coverage of Dr. Oz's 750-drug announcement, the TrumpRx program has continued expanding — the White House confirmed in a May 18 fact sheet that over 600 generic medications were added to TrumpRx.gov, and Fox News reported this week the total catalog has now crossed 800 drugs.

That's a meaningful jump.

What TrumpRx Actually Does

The White House fact sheet is unusually clear about the mechanics. TrumpRx.gov is a price comparison platform, not a government pharmacy. It pulls cash prices from Amazon Pharmacy, Cost Plus Drugs, and GoodRx and lists them in one place.

If you're uninsured or your co-pay is higher than the cash price, this site could genuinely save you money. If you already have solid prescription coverage, it probably doesn't change your life.

The generic drugs now listed include household names: atorvastatin (cholesterol), lisinopril (blood pressure), metformin (diabetes), and clopidogrel (blood thinner). According to the White House, these are among the most commonly used medications in the country. Putting their cash prices in one searchable place is a useful thing.

What It Doesn't Cover

The White House fact sheet is also explicit about the limits. TrumpRx does NOT list controlled substances. It doesn't cover drugs with FDA-mandated risk evaluation and mitigation strategies. It skips medications not commonly offered through direct-to-consumer channels.

So if you're managing a chronic pain condition or a complex specialty drug regimen, this site isn't built for you.

The generic listings are also separate from the Most-Favored-Nation pricing deals Trump has been negotiating on branded medications. Those are a different track entirely — and the results there remain contested.

The Dr. Oz Factor — Still Unresolved

As we reported June 2, CMS Administrator Dr. Oz has been the public face of this rollout. He also claimed that up to 35% of ACA marketplace enrollees may be fraudulently enrolled — a number he has NOT backed up with audited data.

Oz's track record of promoting unverified health claims is well documented. That doesn't mean TrumpRx is bad policy. It means you should evaluate the platform on its merits, not on the credibility of its pitchman.

The AP's coverage of the May 18 expansion was factually straightforward — they reported the 600-generic addition accurately. Fox News reported the 800-total figure this week. Neither outlet examined whether these cash prices actually compete with what insured Americans pay through their plans.

Aggregation Isn't Innovation

GoodRx already exists. Amazon Pharmacy already exists. Cost Plus Drugs — Mark Cuban's project — already exists and has been publicly available for years. TrumpRx is, at its core, consolidating services that were already free and accessible to anyone with a smartphone.

Aggregation has value. Millions of Americans genuinely don't know these discount programs exist. A government-branded site that points people toward the cheapest option could reduce out-of-pocket spending for lower-income, uninsured, or underinsured Americans.

But the White House calling this a major innovation in drug pricing oversells the accomplishment. Price comparison tools are not new. The government putting its logo on one isn't a structural fix to American drug pricing.

What This Means If You Actually Take Medication

If you're paying full retail at a pharmacy and you're not insured, go check TrumpRx.gov. The cash prices listed through GoodRx and Cost Plus Drugs can be dramatically lower than retail — sometimes 80% or 90% lower on common generics. That's real money.

If you have insurance with decent prescription coverage, your plan's negotiated rates may already beat the cash prices on the site. Compare both. Don't assume either direction.

If you're on a specialty drug, a controlled substance, or a biologic — this site currently has nothing for you.

What Comes Next

TrumpRx is a price transparency tool, not drug pricing reform. It's grown from launch to 800+ drugs in a matter of months, which shows the administration is actively building it out. The May 18 generic expansion is the most substantive addition yet.

Credit it for what it is: a useful aggregator that could help uninsured and underinsured Americans find cheaper generic medications.

Don't credit it for what it isn't: a fix to the structural problem of why Americans pay two to three times what Europeans pay for the same branded drugs. That fight is still ahead — and so far, the results on Most-Favored-Nation pricing are thin.

The administration built a useful tool. Now they need to stop calling it historic.